E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Apnea hypopnea syndrome |
El síndrome de apnea-hipopnea del sueño (SAHS) |
|
E.1.1.1 | Medical condition in easily understood language |
Sleep apnea syndrome |
El síndrome de apnea del sueño |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040976 |
E.1.2 | Term | Sleep apnea syndrome |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the sleep pattern induced by clonidine and propofol in terms of proportion of patients who reach the N2 sleep phase without progressing to other phases during the examination |
? Comparar los perfiles de sueño inducido por clonidina y propofol en cuanto a la proporción de pacientes que alcanzan fase de sueño N2 sin progresar a otras fases durante la exploración. |
|
E.2.2 | Secondary objectives of the trial |
To compare during the examination and by direct observation or blind evaluation: Site of upper airway collapse OAA/s (Observational sedation scale) and BIS (Bispectral Index) Correlation between BIS and EEG Duration and results of the examination |
? Comparar intrapaciente durante la exploración, y mediante observación directa o evaluación ciega: o Lugar de colapso VAS o OAA/s (observational sedation scale) y BIS (bispectral index) o Correlación entre BIS y electroencefalograma. o Duración y resultados de la exploración. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients between 18 and 65 years old - Patients with ASA (American Society of Anesthesiologists) criteria I or II - Patients with Apnea-Hypopnea sleep syndrome of moderate or severe intensity, with no morbid obesity and who do not tolerate CPAP (continuous positive airway pressure) Patients with Apnea-Hypopnea syndrome in which the surgical treatment with mandibular advanced device is indicated - Patients with Apnea-hypopnea sleep syndrome who have not responded to surgical treatment - Informed consent |
? Pacientes mayores de 18 años y menores de 65 años. ? Pacientes con criterios ASA (American Society of Anesthesiologists) I y II. ? Pacientes con SAHS (Síndrome de Apnea-Hipoapnea del sueño) moderado o severo sin obesidad mórbida, que no toleren CPAP (presión positiva continua en la vía aérea) ? Pacientes con SAHS leve o ronquido simple en los que esté indicado el tratamiento quirúrgico o con DAM (dispositivo Avance Mandibular). ? Pacientes SAHS que no hayan respondido al tratamiento quirúrgico. ? Consentimiento informado |
|
E.4 | Principal exclusion criteria |
Age < 18 or > 65 years old Alergic to propofol (ie soya bean or egg) or to clonidine High surgical risk (ASA III or higher) Severe cardiaack blockage (grade 2-3) without a pace maker Non controlled hypotension Severe cardiovascular disease |
? Menores de 18 años ? Alergia a los componentes del propofol (especialmente soja o el huevo) o de la Clonidina. ? Riesgo quirúrgico elevado. (ASA mayor o igual a III) ? Bloqueo cardiaco avanzado (grado 2-3) en ausencia de marcapasos ? Hipotensión no controlada ? Enfermedad cardiovascular grave |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients that reach sleep phase N2 without progressing to deeper sleep phases, assessed by means of hypnogram |
Proporción de pacientes que alcanzan fase de sueño N2 sin progresar a fases de sueño más profundas, evaluado mediante hipnograma |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During the endoscopic examination |
Durante la exploración endoscópica |
|
E.5.2 | Secondary end point(s) |
Mean oxigen saturation BP (Systolic and Dyastolic) Degree of baseline subjective somnolence Degree of reproducibility of the examination Examination of the upper airway collapse areas Characteristics of the snore Duration of the examination (in minutes) Maniouvres that modify the snore/apnea |
? Grado de profundidad anestésica o de consciencia ? Tiempo de saturación inferior al 90% ? Índice de desaturación del 3% ? Índice de apnea-hipopnea ? Porcentaje de fases de sueño ? Frecuencia cardiaca ? Saturación media de oxígeno ? TA (sistólica y diastólica) ? Grado de somnolencia basal subjetiva ? Grado de reproducibilidad de la exploración ? Exploración de las áreas de colapso de VAS (via área superior) ? Características del ronquido ? Tiempo duración de la exploración (min.) ? Maniobras que modifican el ronquido/apnea |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During the endoscopic examination |
Durante la exploración endoscópica |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Evaluación ciega por terceros |
Third party blind evaluation |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Las patient last assessment |
Ultimo paciente, última evaluación |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |